15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Arcutis Biotherapeutics Inc, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $29.00 to $36.00, so the covering firms are broadly aligned. The average target of $34.00 sits 20% above the current $28.43. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 32% this year and 30% next, consensus EPS building from about $0.08 next quarter toward $1.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Arcutis Biotherapeutics Inc.
As of Jul, 5 of 6 firms rate ARQT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ARQT EPS & revenue forecast
EPS · NEXT QUARTER
$0.08
Range $0.00 – $0.16 · 6 analysts · +31% YoY
Next period, 6 analysts expect Arcutis Biotherapeutics Inc to earn $0.08 a share (range $0.00 – $0.16), versus $0.06 a year earlier. Full-year consensus is $0.18, growing to $1.13 the year after.
REVENUE · NEXT QUARTER
$129.8M
Range $124.5M – $135.0M · 6 analysts · +30% YoY
Revenue is expected to reach $129.8M (range $124.5M – $135.0M), +30.0% year-over-year. Full-year consensus is $500.1M, rising to $647.2M next year.
Top analysts covering Arcutis Biotherapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARQT.
#1
Serge Belanger
Needham · Rank #83
Buy
$36.00+26.6% to target
Overall win rate
48%
+ Follow
#2
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
$34.00+19.6% to target
Overall win rate
35%
+ Follow
#3
UE
Uy Ear
Mizuho
Buy
$35.00+23.1% to target
Coverage
—
+ Follow
#4
Seamus Fernandez
Guggenheim
Buy
$35.00+23.1% to target
Coverage
—
+ Follow
#5
Tyler Van Buren
TD Cowen
Buy
$35.00+23.1% to target
Coverage
—
+ Follow
ARQT stock forecast FAQ
What is ARQT's average 12-month price target?+
The 6 analysts with a live target average $34.00 for Arcutis Biotherapeutics Inc over the next 12 months, ranging from a $36.00 high to a $29.00 low.
Is ARQT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ARQT?+
The Street-high target is $36.00 (Needham), and the Street-low is $29.00 (Goldman Sachs). The average of all 6 active targets is $34.00.
How many Wall Street analysts cover ARQT?+
6 analysts have an active rating on Arcutis Biotherapeutics Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering ARQT?+
Among analysts who currently cover ARQT, Serge Belanger of Needham has the strongest overall Quantellect track record (Rank #83). Their current call is Buy with a $36.00 target.
What is Arcutis Biotherapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.08 per share (range $0.00 – $0.16) across 6 analysts. Full-year EPS is projected at $0.18, rising to $1.13 the following year.
How much revenue is Arcutis Biotherapeutics Inc expected to report next quarter?+
Consensus revenue is $129.8M (range $124.5M – $135.0M). Full-year revenue is projected at $500.1M, growing to $647.2M next year.
Have analysts been upgrading or downgrading ARQT lately?+
As of Jul, 5 of 6 firms rate ARQT a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARQT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
